1. Academic Validation
  2. Long noncoding RNA MIAT regulates TP53 ubiquitination and expedites prostate adenocarcinoma progression by recruiting TBL1X

Long noncoding RNA MIAT regulates TP53 ubiquitination and expedites prostate adenocarcinoma progression by recruiting TBL1X

  • Biochim Biophys Acta Mol Cell Res. 2023 Jun 23;119527. doi: 10.1016/j.bbamcr.2023.119527.
Zheng Gong 1 Huijing Zhang 2 Yuntian Ge 1 Peng Wang 3
Affiliations

Affiliations

  • 1 Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, PR China.
  • 2 Department of Endoscopy, The First Affiliated Hospital of China Medical University, Shenyang, PR China.
  • 3 Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, PR China. Electronic address: [email protected].
Abstract

Despite recent advances in Cancer Immunotherapy, their efficacy for treating patients with prostate adenocarcinoma (PRAD) is low due to complex immune evasion mechanisms. However, the function of long non-coding RNA (lncRNAs) in immune evasion has not been fully clarified. This study aimed to expound the role of myocardial infarction-associated transcript (MIAT), a lncRNA significantly upregulated in three PRAD-associated datasets, in immune evasion and try to reveal the potential mechanism. MIAT was highly expressed in PRAD tissues and predicted poor prognosis, and suppression of MIAT inhibited the malignant biological behavior of PRAD cells. Moreover, the depletion of MIAT promoted the immune response of CD8+ T cells and hampered the immune evasion of PRAD cells. In addition, MIAT downregulated TP53 protein expression by recruiting transducin beta-like protein 1X (TBL1X) for ubiquitination modification. Silencing of TP53 or overexpression of TBL1X was enough to abate the tumor suppressive effects of MIAT knockdown in vitro and in vivo. Our results provide evidence for a novel regulation mechanism of CD8+ T cells in PRAD and MIAT may serve as a potential therapeutic target in PRAD.

Keywords

Immune evasion; Long noncoding MIAT; Prostate adenocarcinoma; TBL1X; TP53.

Figures
Products